The April 2011 HIV PJA Strategy Webinar again revisited the subject of Pre-Exposure Prophylaxis (PrEP) as a biomedical HIV prevention intervention. Experts discussed a recent closure of a PrEP clinical trial among African women, the outlook for U.S. pricing and FDA approval, as well as the ethics of ensuring community access.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…